We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Avastin/FOLFOX4 Improves Overall Survival in Pts With Advanced Colon Ca

Jan 1, 2005
Volume: 
14
Issue: 
1
  • Colorectal Cancer

BETHESDA, Maryland—Data from the randomized, phase III E3200
trial show that patients with advanced colorectal cancer who were treated with
bevacizumab (Avastin) in combination with the oxaliplatin (Eloxatin)-based
regimen known as FOLFOX4 had a significant survival advantage, compared with
patients treated with FOLFOX4 alone. The National Cancer Institute (NCI)
released the results from an interim analysis at the recommendation of the
trial’s data monitoring committee (DMC), after the trial monitors determined
that the study had met its primary endpoint of improved overall survival.

Patients treated with bevacizumab and FOLFOX4 (oxaliplatin,
fluorouracil, and leucovorin) had a median overall survival of 12.5 months vs
10.7 months for those receiving FOXFOX4 alone. The difference represented a 17%
improvement in median overall survival and a 26% reduction in the risk of death
for the bevacizumab arm.

"We now know that bevacizumab added to second-line
chemotherapy with FOLFOX4 improves survival," said study chair Bruce J.
Giantonio, MD, of the University of Pennsylvania’s Abramson Cancer Center.
"With these findings, we can now more confidently expect survival for people
with advanced disease to be more than double what it was just a few years ago."
Dr. Giantonio said that preliminary results of the E3200 trial will be
presented at the American Society of Clinical Oncology’s Gastrointestinal
Cancers Symposium this month.

Bevacizumab binds to and inhibits vascular endothelial
growth factor (VEGF), a crucial player in tumor angiogenesis. Oxaliplatin is a
novel platinum-based anticancer drug that destroys cancer cells. "The results
of this study are very important for all those living with advanced colorectal
cancer," said NCI director Andrew C. von Eschenbach, MD. "They provide further
confirmation that a biologic agent that targets a tumor’s blood supply can
prolong survival when combined with chemotherapy, even for patients who have
previously received therapy for advanced disease."

NCI sponsored the 829-patient trial, which was conducted by
a network of researchers led by the Eastern Cooperative Oncology Group. Accrual
occurred between October 2001 and April 2003. Investigators accepted advanced
colorec-tal patients previously treated with a fluorouracil-based therapy and
irinotecan (Camptosar), alone or at the same time, who had advanced disease or
a relapse within 6 months of adjuvant treatment.

Patients were randomized to three groups: FOLFOX4 plus bevacizumab, standard
FOLFOX4 treatment only, or bevacizumab only. In March 2003, trial investigators
stopped randomizing patients to the bevacizumab-only arm after the DMC found
that early data indicated this group of patients might have a lower overall
survival than those in the other two arms. The treatment toxicities associated
with bevacizumab were consistent with previous trials in which the drug was
combined with chemotherapy. 


Related Articles

  • ctDNA Increase May Predict Regorafenib Response in Advanced CRC
  • Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
  • ACS Nutrition, Activity Guidelines Boost Survival in Stage III CRC
  • Modified XELIRI Noninferior to FOLFIRI for Metastatic CRC
  • A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.